Text Size

Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness

Sharif NA.


  • 2023
  • Exp Eye Res
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Institute of Ophthalmology, University College London (UCL), London, UK; Imperial College of Science and Technology, St. Mary's Campus, London, UK; Eye-ACP Duke-National University of Singapore Medical School, Singapore; Singapore Eye Research Institute (SERI), Singapore; Department of Pharmacy Sciences, Creighton University, Omaha, NE, USA; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, Texas, USA; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA; Ophthalmology Innovation Center, Santen Inc USA, Emeryville, CA, USA

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022